Compare Cassava Sciences Inc (FLNA) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Direxion Daily FTSE China Bull 3x Shares trades at $25.13 (market cap $560.32M). The key difference: Direxion Daily FTSE China Bull 3x Shares is far larger — about 14.2× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 1,009,521). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Direxion Daily FTSE China Bull 3x Shares for 25 Days on average.
| FLNA | YINN | |
|---|---|---|
Market Cap | $39.40M | $560.32M |
Volume | 759,018 | 1,009,521 |
Sector | Health | Leveraged / Inverse |
52-Week High | $4.64 | $52.69 |
52-Week Low | $0.68 | $21.45 |
Typical Hold Time | 37 Days | 25 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
YINN is trading at $25.09, up 6.49% in the past 24 hours, though technical indicators signal a bearish trend with 17 sell signals versus 2 buy signals. The stock faces resistance at $24 with support at $23. Recent news highlights China's economic policies and export controls, which may impact the underlying index exposure. Financial ratios remain unavailable for analysis.
The outlook is cautious due to bearish technicals and China-related macroeconomic risks. Opportunities exist if support holds and sentiment improves, but investors face volatility from regulatory developments and weak momentum. Risk management is essential given the conflicting signals between price action and technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
